Restoration Hardware Holdings Inc
Latest Restoration Hardware Holdings Inc News and Updates
Teva Pharmaceutical: Earnings Trends and Recent Developments
Teva Pharmaceutical’s net income and diluted EPS in the first nine months of 2018 amounted to $541.0 million and $0.53, respectively.
Eylea’s Net Sales in the US Jumped in 4Q15, but Was It High Enough?
Eylea, the leading product in Regeneron Pharmaceuticals’s (REGN) portfolio, fetched $746 million during the fourth quarter of 2015 in the US.
What Could Expand Keytruda’s Revenues?
In addition to the US market, Merck’s (MRK) Keytruda has been approved in more than 50 international markets for metastatic melanoma.
How Biogen’s Tysabri and Zinbryta Performed in 1Q17
In 1Q17, Biogen (BIIB) saw an increased demand for Tysabri, both in the United States and in international markets.
How Vertex Pharmaceuticals’ Drugs Performed in 1Q18
In 1Q18, Vertex Pharmaceuticals’ (VRTX) Orkambi revenue rose ~20% YoY (year-over-year) to $354 million from $295 million.
Why Eylea Could Face Tough Competition in 2016
In 2016, Regeneron expects to face increased competition from Roche Holding’s Lucentis (Ranibizumab) and Avastin (Bevacizumab) for Eylea.
AstraZeneca and Its Oncology Segment’s Growth in 2Q16
AstraZeneca’s (AZN) oncology segment is another key focus area. The segment’s contribution increased to more than 15% in 2Q16.
A Post-2Q17 Update on Pfizer’s Oncology Drugs: Sutent, Xalkori, and Inlyta
In 2Q17, Inlyta generated revenues of ~$88 million, which represents an ~19% decline on a YoY basis and ~4% growth on a quarter-over-quarter basis.
Amgen’s Nephrology Drugs Expect Falling Revenue in 4Q15
Analysts projected a fall in the revenue for Amgen’s nephrology drugs, Aranesp and Epogen, in 4Q15. The drugs are expected to suffer in the coming quarters.
AstraZeneca’s New Oncology Portfolio May See Healthy Growth
In 1Q17, AstraZeneca’s (AZN) new oncology portfolio reported global sales of around $236.0 million. Tagrisso earned revenues of $171.0 million globally.
Gilead Sciences’ Product Line Extension
As part of its significant product line extension, Gilead Sciences (GILD) is entering therapeutic areas such as oncology, pulmonology, and cardiology.
Worst-Case Scenario for Regeneron: What If Eylea Sales Slow Down by 2018?
Regeneron Pharmaceuticals (REGN) depends heavily upon its key drug, Eylea, which recorded global sales of $4.1 billion during fiscal 2015.
Why NICE Didn’t Approve Roche’s Ocrevus for Multiple Sclerosis
On April 5, 2018, Roche’s (RHHBY) MS (multiple sclerosis) drug Ocrevus was denied recommendation by NICE.
Ibrance Is the Only Registered CDK 4/6 Inhibitor for Breast Cancer
Since its launch in February 2015, Pfizer’s Ibrance has quickly captured the advanced breast cancer market and has reached more than 40,000 patients.
How Regeneron Is Working to Maintain Eylea’s Dominance
Regeneron’s (REGN) flagship product, Eylea (Aflibercept), was launched in the US in November 2011.
AstraZeneca Is Taking Steps to Improve Its Position in Oncology
During the last quarter, the oncology segment’s contribution to AstraZeneca (AZN) increased to over 15%. AZN’s key products for oncology are Zoladex, Faslodex, Iressa, and the new drug Tagrisso.
Tesaro Stock Up over 16% on Rumors of Acquisition by Roche
Yesterday, Tesaro (TSRO) stock rose ~16.3%, triggered by rumours of an acquisition bid by Roche (RHHBY), which registered a stock price rise of ~2.1%.
What Were Pfizer’s Major Achievements in 2016?
During 2016, Pfizer (PFE) succeeded in expanding its label for Ibrance, its breast cancer treatment.
Sales Performance Analysis of Roche’s Pharmaceuticals Division
Roche Holding (RHHBY) generated ~78% of its group sales from the pharmaceuticals division.
Durvalumab and Tagrisso May Boost AstraZeneca’s Revenues in 2017
On December 9, 2016, the FDA accepted for review its first-ever biologics license application (or BLA) submitted by AstraZeneca (AZN).
The High Hope of Exelixis’s Cabometyx Label Expansion
Exelixis (EXEL) plans to explore Cabometyx in combination with immune checkpoint inhibitors such as atezolizumab, ipilimumab, and nivolumab.
What Drove Regeneron’s 3Q16 Performance?
In fiscal 3Q16, Regeneron Pharmaceuticals (REGN) recorded revenue amounting to $1.2 billion and net product sales amounting to $857 million.
AstraZeneca’s Key Focus: Oncology
AstraZeneca’s (AZN) key focus is its oncology segment. The segment’s contribution increased to more than 12% in 1Q16. Its key products include Zoladex, Faslodex, and Iressa.
Tagrisso Expected to Be a Key Growth Driver for AstraZeneca in 2017
Launched in Japan in 2Q16, AstraZeneca’s (AZN) 1Q17 revenues for Tagrisso approached $39 million in this major emerging market.
This Could Be a Solid Growth Driver for Myriad Genetics in 2018
Myriad Genetics (MYGN) announced the U.S. Food and Drug Administration’s (or FDA) acceptance of its supplementary premarket approval application for BRACAnalysis CDx, a DNA sequencing companion diagnostic test.
Oncology Segment: Another Growth Platform for AstraZeneca?
The oncology segment is another key focus area of AstraZeneca (AZN). The oncology segment’s contribution increased from ~11.6% in 2014 to ~12.1% in 2015.
International Mutual Funds: Could They Be Suitable for You?
For those investors who want to invest in international mutual funds, we’ve quantitatively analyzed the composition and performance of nine of them.
The Latest on TEVA’s Oncology Business
In 1H17, Teva Pharmaceutical’s (TEVA) oncology business generated revenues of ~$550 million, or ~9% lower YoY (year-over-year).
Xtandi’s Prescription Volumes Continue to Rise in 2017
In this series, we’ll look at Pfizer’s main revenue drivers in 2017, and what could steer its performance in 2018.
Inside Roche’s Strategy to Offset Revenue Declines
Roche’s big three contributors include MabThera/Rituxan, Herceptin, and Avastin, which accounted for 14.7%, 13.9% and 13.7% of revenues in fiscal 1Q16.
How’s Celgene’s Abraxane Positioned after 4Q17?
In 4Q17, Celgene’s (CELG) Abraxane generated revenues of $251 million, which reflected a decline of ~6% on a YoY (year-over-year) basis.
Why GlaxoSmithKline’s Pharmaceuticals Business Grew
GlaxoSmithKline is a major shareholder of ViiV Healthcare. Its HIV products reported revenue of 1.12 billion pounds during 2Q17.
Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class
The PD-1 (programmed death-1)/PD-L1 (programmed death-ligand 1) class consists of Bristol-Myers Squibb’s Opdivo, Merck’s Keytruda, and Roche’s Tecentriq.
What Drove Gilead Sciences’ Hepatitis C Portfolio in 3Q15?
Gilead Sciences’ (GILD) hepatitis C (or HCV) portfolio is expected to continue driving the company’s revenues and net profit margins in 3Q15.
What Can Investors Expect from Regeneron’s 4Q15 Earnings?
Regeneron will report its earnings for 4Q15 and fiscal 2015 on February 9, 2016. It will report the earnings before the financial markets open in the US.
Ignyta’s Drug Pipeline
Ignyta (RXDX) has completed enrollment for a Phase 1 clinical trial of RXDX-105, an orally bioavailable small molecule tyrosine kinase inhibitor.
What Are Mylan’s Key Growth Drivers in Fiscal 2019?
In fiscal 2018, Mylan (MYL) reported revenues of $11.43 billion, a YoY decline of 4%.
A Look at Spark’s Potential Revenue Contribution to Roche Holdings
Wall Street analysts have projected Spark Therapeutics’ revenues to be $105.64 million, $169.22 million, and $263.76 million for fiscal 2019, fiscal 2020, and fiscal 2021, respectively.
Roche Holdings to Acquire Spark Therapeutics
On February 25, Roche Holdings (RHHBY) issued a press release announcing that it has entered a definitive agreement to acquire Spark Therapeutics (ONCE).
How Pfizer’s Sutent and Xalkori Have Performed
In the first nine months of this year, Pfizer’s (PFE) Sutent sales fell 2% YoY (year-over-year) to $785.0 million from $805.0 million.
A Financial Overview of Ionis Pharmaceuticals in October
Ionis Pharmaceuticals generated Q2 2018 revenues of $118.0 million compared to $122.3 million in Q2 2017, which reflected ~15.0% YoY growth.
An Overview of Roche’s Immunology Drugs Pulmozyme and CellCept
Roche’s CellCept generated revenues of 333.0 million Swiss francs in H1 2018 compared to 346.0 million Swiss francs in H1 2017.
An Overview of Roche’s Hemato-Oncology Drugs MabThera and Gazvya
Roche’s (RHHBY) MabThera/Rituxan reported revenues of 3.45 billion Swiss francs in the first half compared to 3.8 billion Swiss francs in the first half of 2017.
Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label
On March 19, Regeneron announced positive top line results from its Phase 3 PANORAMA trial.
Biogen and Ionis Crash on PTC Therapeutics’ Promising Data
Yesterday, PTC Therapeutics (PTCT) registered a stock price rise of ~24.6% on the positive data the company presented along with partner Roche (RHHBY) for their SMA (spinal muscular atrophy) drug risdiplam.
Envision Healthcare to Be Acquired by KKR
On June 11, Envision entered into a definitive acquisition agreement with KKR.
Opdivo May Witness Decline in This Target Patient Population
At the end of Q1 2018, Bristol-Myers Squibb’s (BMY) Opdivo earned 40% of its revenues in the US market from the lung cancer indication.
Analyzing Roche’s Acquisition of Flatiron Health
Raxibacumab has orphan drug designation in the US and was approved by the FDA in 2012.
A Look at Novartis’s Immunology and Dermatology Segment’s Performance
In 4Q17, Novartis’s Immunology and Dermatology segment generated revenues of $1.2 billion, ~30% growth on a year-over-year (or YoY) basis and ~9% growth quarter-over-quarter.
How Novartis’s Ophthalmology Business Performed in 2017
In 4Q17, Novartis’s Ophthalmology business generated revenues of $1.35 billion, which reflected ~2% growth on a year-over-year (or YoY) basis and ~2% growth quarter-over-quarter.
How Did Novartis’s Affinitor, Exjade, and Tafinlar+Mekinist Perform in 2017?
In 4Q17, Novartis’s (NVS) Afinitor generated revenues of $407 million compared to $391 million in 4Q16, which reflected ~4% growth on a year-over-year (or YoY) basis and ~5% growth quarter-over-quarter.
How Gilead Sciences’ Ranexa, AmBisome, Zydelig, and Vosevi Performed
In 4Q17, Gilead Sciences’ (GILD) Ranexa generated revenues of $200 million, which reflected a ~5% decline on a year-over-year (or YoY) basis and 22% growth quarter-over-quarter.
Teva Terminates TV-45070 Development Agreement with Xenon
On March 7, Teva and Xenon entered into a mutual agreement to terminate the collaborative development and license agreement they entered into in 2012.
What Happened with Merck’s Keytruda in 2017?
In 4Q17, Merck’s (MRK) Keytruda generated revenues of $1.3 billion, compared with $483 million in 4Q16.
Semaglutide May Prove to Be an Effective Anti-Obesity Therapy
Novo Nordisk plans to initiate its Phase 3a program, STEP, to study the efficacy of 2.4 mg of semaglutide once per week in obesity indications in 1H18.
Saxenda May Continue to Lead in the Diabetes Segment in 2018
In 2017, Novo Nordisk’s (NVO) Saxenda sales reached 2.6 billion Danish kroner, a YoY (year-over-year) rise of 64%.
Novartis’ Kymriah: The First Gene Therapy to Be Approved in the US
The National Cancer Institute estimates that the incidence of ALL in patients aged 20 or younger is ~3,100 in the US.
Pfizer’s Inlyta: Analyzing Revenue Trends
In 4Q17, Pfizer’s Inlyta generated revenues of $83 million, which is a 14% decline YoY and a 1% decline on a quarter-over-quarter basis.
Analysts’ Updates after Sanofi’s Bioverativ Announcement
In this article, we’ll have a look at Wall Street’s recommendations and target prices following Sanofi’s Bioverativ acquisition announcement.
How Is Novartis’s Tafinlar+Mekinist Positioned for 2018?
In 1Q17, 2Q17, and 3Q17, Tafinlar+Mekinist reported revenues of $187 million, $216 million, and $224 million, respectively.
What Analysts Recommend for Roche in January 2018
In December 2017, Roche and Ignyta entered a merger agreement where Roche will fully acquire Ignyta at a price of $27.0 per share in an all-cash transaction.
Zelboraf Could Boost Roche’s Sales Growth in 2018
Roche’s (RHHBY) Zelboraf (vemurafenib) is indicated for the treatment of individuals with unresectable or metastatic melanoma with the BRAF V600 mutation.
Mavyret May Prove a Strong Growth Driver for AbbVie Going Forward
In 3Q17, AbbVie (ABBV) reported global sales of nearly $276 million for its hepatitis C (or HCV) portfolio, which reflected a 27.7% operational fall.
Approval of Alecensa in Europe Could Boost Roche’s Revenue Growth
In 1Q17, 2Q17, and 3Q17, Roche’s Alecensa reported revenues of 68 million Swiss francs, 80 million Swiss francs, and 96 million Swiss francs, respectively.
What to Expect from Roche’s Tecentriq and Avastin in 2018
In 1Q17, 2Q17, and 3Q17, Roche’s (RHHBY) Avastin generated revenues of 1.68 billion Swiss francs, 1.7 billion Swiss francs, and 1.6 billion Swiss francs, respectively.
How Is Roche’s Hemlibra Positioned for 2018?
Roche’s (RHHBY) Hemlibra is used for the prevention and reduction of the frequency of bleeding episodes in individuals with hemophilia A with factor VIII inhibitors.
What to Expect from Roche’s Investigational Drug Polatuzumab Vedotin
In December 2017, Roche (RHHBY) presented the results of its randomized phase two GO29365 trial.
Perjeta Could Significantly Boost Roche’s Revenue Growth in 2018
In December 2017, the Food and Drug Administration approved Roche’s (RHHBY) Perjeta based on the results of its phase three Aphinity trial.
Pfizer Is Pursuing Oncology, Inflammation, and Immunology Research
On May 9, 2017, the US Food and Drug Administration (or FDA) approved Pfizer (PFE) and Merck’s Bavencio (avelumab) as a treatment option for patients suffering from locally advanced or metastatic urothelial carcinoma (or UC).
A Look at AstraZeneca’s Iressa, Zoladex, Casodex, and Arimidex
In 3Q17, AstraZeneca’s (AZN) Iressa generated revenues of $137.0 million, which reflected ~10.0% growth on a year-over-year basis.
An Update on Eli Lilly’s Oncology Drugs: Alimta, Erbitux, and Gemzar
In 3Q17, Eli Lilly’s (LLY) Alimta generated revenues of $514.5 million, a ~10% increase on a year-over-year (or YoY) basis and a 3% decline on a quarter-over-quarter basis.
Myriad Genetics Saw Positive Results from GeneSight Trial
Myriad Genetics (MYGN) announced positive results from its Impact study, which evaluated the effectiveness of the GeneSight precision medicine test.
How Has Eli Lilly’s Cyramza Performed
In 3Q17, Eli Lilly’s (LLY) Cyramza generated revenues of $196 million, which reflected ~23% growth on a YoY basis and 5% growth on a quarter-over-quarter basis.
Reimbursement for Myriad Genetics’ GeneSight in Fiscal 2018
In fiscal 2018, Myriad Genetics (MYGN) expects to witness rapid expansion in reimbursement for GeneSight based on positive results of the 1,200-patient pharmacogenomic study.
Myriad Genetics’ GeneSight: A Major Growth Driver in 2018?
In the first quarter of fiscal 2018, Myriad Genetics’ (MYGN) GeneSight reported revenues of $28.8 million, which is a YoY growth of 54% and a sequential growth of 12%.
BRACAnalysis CDx Received FDA Approval for Ovarian Cancer Indication
On March 27, 2017, the FDA also approved BRACAnalysis CDX test as a complementary diagnostic test to be used with ovarian cancer maintenance therapy Tesaro’s (TSRO) Zejula (miraparib).
A Look at How These Pfizer Drugs Have Performed in 2017
In 3Q17, Pfizer’s (PFE) Celebrex generated revenues of $212 million, a ~9% increase on a year-over-year (or YoY) basis and a 19% increase on a quarter-over-quarter basis.
An Update on Bristol-Myers Squibb’s Eliquis, Orencia, and Empliciti
In 3Q17, Bristol-Myers Squibb’s (BMY) Eliquis generated revenues of $1.2 billion, a ~39% increae on a year-over-year (or YoY) basis and 5% growth on a quarter-over-quarter basis.
An Update on Pfizer’s Xalkori and Inlyta
In 3Q17, Pfizer’s (PFE) Xalkori reported revenues of $146 million, which is ~4% growth on a year-over-year (or YoY) basis and 6% growth on a quarter-over-quarter basis.
How Have Pfizer’s Ibrance and Sutent Performed in 2017?
In 3Q17, Pfizer’s (PFE) Ibrance generated revenues of $878 million, a ~60% increase on year-over-year (or YoY) basis and ~3% growth on a quarter-over-quarter basis.
Could Lorlatinib Be a Long-Term Growth Driver for Pfizer?
Lorlatinib is Pfizer’s (PFE) investigational next-generation ALK/ROS-1 tyrosine kinase inhibitor in clinical trials to evaluate its safety and efficacy in the treatment of ALK-positive metastatic non-small cell lung cancer.
Inside Exelixis’s Label Expansion Collaborations for Cabozantinib
As a part of the broader lifecycle management for Cabometyx, Exelixis is exploring the drug in combination with other immune checkpoint inhibitors.
Behind Exelixis’s Cabometyx Strategy for 2018
Exelixis (EXEL) expects the FDA’s approval for Cabometyx for first-line RCC (renal cell carcinoma) to be a major revenue driver.
How Celgene’s Abraxane Is Positioned after 3Q17
In 3Q17, Celgene’s (CELG) Abraxane generated revenues of $251.0 million, which reflected ~8.0% growth on a year-over-year basis.
How Roche’s Oncology Drug Gazyva Is Positioned after 3Q17
In 3Q17, Roche’s (RHHBY) Gazyva generated revenues of 69 million Swiss francs, which reflected ~34% growth on a year-over-year (or YoY) basis.
How Is Cabometyx and Cometriq Positioned after 1H17?
In 2Q17, Exelixis’s (EXEL) Cabometyx generated revenues of ~$80.9 million compared to ~$17.6 million in 2Q16.
Medtronic Saw Several Challenges during Launch of MiniMed 670G
In fiscal 2H17, Medtronic launched the priority access program to first target those patients who were interested in purchasing MiniMed 670G.
What’s Medtronic’s Long-Term Growth Strategy for Its Diabetes Business?
Medtronic (MDT) expects its diabetes business to witness a temporary sequential drop in revenues in 2Q18 and then return back to growth in the second half of fiscal 2018.
What’s Medtronic’s Strategy to Drive Growth in Diabetes Group?
In the US, Medtronic has entered outcomes-based contracts with UnitedHealth Group and Aetna.
Roche’s Immunology Drugs Xolair, Pulmozyme, and CellCept
In the first half of 2017, Roche’s (RHHBY) Xolair reported revenues of CHF 866.0 million, which is a 17.0% rise on a YoY (year-over-year) basis.
Esbriet Could Boost Roche’s Revenue Growth in 2H17
In the first half of 2017, Roche’s (RHHBY) Esbriet reported revenues of CHF 418.0 million, which reflected a ~16.0% growth on a YoY basis.
An Update on Novartis’s Tafinlar and Mekinist post 1H17
In 1H17, Novartis’s (NVS) Tafinlar & Mekinist reported revenues of around $403 million, which reflected ~25% growth on a year-over-year (or YoY) basis.
Kisqali Could Significantly Boost Novartis’s Revenue Growth
In 1H17 and 2Q17, Novartis’s (NVS) Kisqali reported revenues of around $15 million and $8 million, respectively.
How Did Novartis Perform in 1H17?
In 1H17, Novartis (NVS) reported revenues of around $23.8 billion, a ~1% decline on a year-over-year (or YoY) basis.
How Is Novartis’s Lucentis Positioned after 1H17?
In 1H17, Novartis’s (NVS) Lucentis reported revenues of around $922 million, which is a ~1% decline on a year-over-year (or YoY) basis.
What to Expect from Pfizer’s Biosimilars Business
In 2Q17, Pfizer’s Inflectra/Remsima reported revenues of ~$94 million compared to $45 million in 2Q16.
Promacta: A Major Growth Driver for Ligand Pharmaceuticals in 2017
Promacta was discovered by Ligand Pharmaceuticals (LGND) and GlaxoSmithKline (GSK) as a part of their thrombopoietin (or TPO) receptor agonist research collaboration.
Talazoparib Could Be a Significant Long-Term Growth Driver for Pfizer
In June 2017, Pfizer (PFE) presented the results from the Phase 2 ABRAZO trial.
Keytruda Is Expected to Drive Merck’s Revenue Growth in 2H17
The FDA approval of Keytruda as a first-line therapy was based on data from the KEYNOTE-052 trial.
Opdivo Could Drive Bristol-Myers Squibb’s Revenue Growth in 2017
In 2Q17, Bristol-Myers Squibb’s (BMY) Opdivo generated revenues of around $1.2 billion, which reflected ~45% growth on a year-over-year basis.